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Objective. Although tetracyclines are used for topical therapy in recurrent aphthous stomatitis (RAS) patients, there are few
clinical trials that have used doxycycline. Hence, we evaluated the therapeutic efficacy of topical doxycycline hyclate in RAS.
Study design. A single-blinded placebo-controlled trial comprising 50 RAS subjects divided into group A and group B with 25
subjects in each group was performed. Patients in group A received topical application of crushed doxycycline hyclate tablet
with denture adhesive and few drops of saline solution once at the initial visit. Group B received placebo similarly. Treatment
response was assessed by measures of pain reduction, ulcer duration, and adhesive retention time. Data were analyzed using
the Student t test.
Results. Participants treated with doxycycline hyclate had significantly less pain by day 1 (P < .001) and healed faster
(P < .001) compared with placebo.
Conclusion. A single application of doxycycline hyclate decreased pain and speeded recovery. (Oral Surg Oral Med Oral
Pathol Oral Radiol 2013;116:440-446)Recurrent aphthous ulcers (RAUs) are currently one of
the most common oral disorders and are known to
affect 20% of the population at sometimes in their
lives.1 Recurrent aphthous stomatitis (RAS) is an
inﬂammatory condition of unknown etiology charac-
terized by painful, recurrent, single, or multiple ulcer-
ations of the oral mucosa.2 RAS is found in men and
women of all races and geographic regions.3
The etiopathogenesis of the disease is obscure.
Despite extensive investigations, studies have failed to
ﬁnd the exact etiology and pathophysiology of RAS.
Heredity, hematinic deﬁciencies, immune dysregula-
tion, some foods, drugs, stress, local trauma, mechan-
ical injury hormonal disturbances, infections, smoking
habits, and poor oral hygiene are proposed factors.4,5 It
has been suggested that interstitial collagenases
[matrix metalloproteinase-1 (MMP-1) and MMP-8]
play a major role in tissue destructive events in RAU.6
The most common clinical presentation of the
disease is recurrent, round, clearly deﬁned small painful
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440and erythematous halos.2 The duration of the ulcers is
usually 7-10 days.7
A multitude of treatment modalities are used for the
symptomatic management of aphthous ulcers. Standard
topical treatment options that provide symptomatic relief
include analgesics, anesthetics, antiseptics, anti-inﬂam-
matory agents, steroids, sucralfate, tetracycline suspen-
sion, and silver nitrate. Dietary modiﬁcations may also
support therapeutic measures. In resistant cases of aph-
thous ulcers or aphthous ulcers with systemic involve-
ment, systemic treatment can be selected from a wide
spectrum of immunomodulators that include dexameth-
asone, tacrolimus, azathioprine, cyclophosphamide,
colchicine, prednisolone, cyclosporine A, interferon-a,
tumor necrosis factor-a antagonists, antimetabolites, and
alkylating agents.8-10
Despite the many therapeutic options available for
the management of RAS, no treatment is speciﬁc and
deﬁnitive.11 Systemic and topical tetracycline regimens
have been used since several decades in the treatment of
RAS.8-10 Traditionally, the use of doxycycline for the
management of RAS was based on its antimicrobial
property. However, newer properties of doxycycline
such as inhibition of prostaglandin production,Statement of Clinical Relevance
A single application of topical doxycycline hyclate
with denture adhesive as vehicle over aphthous
ulcers was shown to be efﬁcacious in reducing pain
on the ﬁrst posttreatment day compared with
placebo.
Fig. 1. (A) Doxycycline hyclate group e pretreatment, (B) application of doxycycline hyclate to the ulcer, and (C) doxycycline
hyclate group on 10th day posttreatment.
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and gelatinase have further promoted its use as an
effective modality in the management of this disease.6
Although RAS is not life threatening, it adversely
affects the quality of life. Despite the self-limiting
nature of the disease, the pain and ulceration cause
suffering in affected patients.2 Many nascent protocols
have emerged to combat the challenge posed by these
tiny but painful ulcers. One such therapeutic strategy to
alleviate pain caused by aphthous ulcers is a single
application of a topical antibiotic. Most therapeutic
regimens implicated in the past dictate the use of
medication throughout the course of the ulcer.
However, the aim of the present study is to evaluate the
efﬁcacy of topical application of doxycycline hyclate
only once as a new therapeutic regimen in the treatment
of minor RAU for pain reduction.
MATERIALS AND METHODS
A randomized, single-blinded, placebo-controlled study
was conducted in the Department of Oral Medicine and
Radiology, College of Dental Sciences, Davangere,
Karnataka, India. The study group comprised 50
subjects of either sex above the age of 16 years.
Diagnosis of RAS was made on the basis of natural
history and clinical features.
Patients who are physically healthy with history of
duration of ulcers for more than 24 h and not exceeding
72 h with symptoms that is pain and burning sensation
secondary to oral aphthous ulcers and with the char-
acteristic clinical features of recurrent minor oral aph-
thous ulcers6 were included in the study. Pregnant and
lactating women,6 patients with any other coexisting
oral mucosal diseases, hematologic abnormalities,
history of hypersensitivity to tetracyclines,6 end stage
renal disease, or those taking any other medications for
RAS were excluded from study.12
All participants were explained the need and design of
the study, beneﬁts of the pharmacologic therapy,
possible adverse effects, and possibility of beingallocated to the placebo group at the start of the study.
Only those patients who gave a signed informed consent
on an institutionally approved document participated.
Drugs used for the study included doxycycline hyclate
100 mg tablets (Doxt 100) manufactured by Dr Reddy’s
and placebo 100 mg tablets (starch, lactose, sodium
starch glycolate, talc, and magnesium stearate) prepared
by TIFAC CORE HD, J.S.S. College of pharmacy,
Rocklands, Ooty.
Clinical examination was carried out wearing sterile
hand gloves and mouth mask, with the patient seated in
a dental chair. The initial appointment consisted of col-
lecting the demographic data, general history, a history
of patient’s past experiences with the lesions and a clin-
ical examination. Treatment was administered on the
day of the initial visit. Under adequate illumination,
a pair of sterile mouth mirror was used to examine the
lesion. A diagnosis of aphthous ulcer was made if it
occurred in the nonkeratinized mucosa as a shallow
crateriform ulcer covered by a whitish yellow pseudo-
membrane and presented with a round, regular border
with a surrounding erythematous halo.13
On clinical examination, pain intensity using a visual
analog scale (VAS) of 0-10 (with 1 mm division, where
‘0’ is no pain and ‘10’ is worst possible pain), number
of ulcers, size of each ulcer (a graduated periodontal
probe was used to measure the ulcer size at the
maximum diameter of the ulcer), and the duration of
each ulcer (the day of onset of the ﬁrst prodromal
symptom of each ulcer) were recorded.
The 50 patients included in the study were divided
into 2 groups, group A and group B. Every alternate
patient was allocated to each group. In group A, 25
patients received powdered doxycycline hyclate tablet
topically whereas in group B, 25 patients received
powdered placebo tablet topically.
After complete clinical examination of the ulcer,
pretreatment photographs were taken before the start of
treatment (Figures 1A and 2A). The ulcer and the
mucosa surrounding the ulcer were dried thoroughly.
Fig. 2. (A) Placebo group e pretreatment, (B) application of placebo to the ulcer, and (C) placebo group on 10th day posttreatment.
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duct openings. The doxycycline hyclate or the placebo
tablet was ground to ﬁne powder using a glass mortar
and pestle. An appropriate amount of the medicament
or placebo, roughly corresponding to the size of the
ulcer was mixed with a pinch of denture adhesive in
a dappen dish using a stainless steel cement spatula.
Fifty percent of the medicament or placebo was used
for ulcers <5 cm and 100% of the medicament was
used for ulcers >5 cm. A few drops of saline solution
were added to this mixture. Then, the ﬁnal mixture was
placed over the ulcer using a plastic instrument
(Figures 1B and 2B). After topically applying the
medicament or the placebo over the ulcer, the patient
was asked to refrain from eating or drinking for a period
of 2 h.
A single application of the medicament or placebo
was done during the patient’s initial visit and every
patient was recalled after 10 days following the treat-
ment procedure. A pain scale sheet to record the daily
status of the patient was given at the initial visit. The
patients were instructed to self-evaluate the pain scale
sheet on the day after treatment and daily after that for
10 days. After 10 days, the patients were asked to
return the pain scale record. Patients were questioned
about any adverse effects following drug therapy. The
patients were also asked to record the adhesive reten-
tion time in the oral cavity and mark the day when the
ulcer healed by looking at the mirror and using the
pain scale sheet provided to the patient. Posttreatment
follow-up involved the evaluation of patient on the
10th day. The pain scale sheet was collected from the
patient and posttreatment photographs were taken for
comparing with the baseline (Figures 1C and 2C).
Response to the drug therapy was assessed on the
basis of pre- vs posttreatment scores. The rate of
ulcer healing and adhesive retention time in both the
groups was also compared. Intragroup comparisons
of posttreatment pain reduction were performed using
paired t test. Intergroup comparisons of posttreatment
pain reduction, the rate of ulcer healing, and theadhesive retention time were performed using
unpaired t test.
RESULTS
A total of 50 patients with age ranging from 16 to 65
years (mean age of 25.14 years) were enrolled for
study, among these 20 were females and 30 were males.
There were 29 ulcers in group A in 25 patients; 4
patients had 2 ulcers. There were 26 ulcers in group B
in 25 patients; 1 patient had 2 ulcers.Pain incidence in VAS before and after treatment
The mean pain score at baseline for the patients of
group A was 6.4  2.3. The mean pain scores on day 1,
2, 3, 4, 5, and 6 were 3.7  2.2, 2.3  1.8, 0.9  1.2,
0.4  0.9, 0.1  0.4, and 0.1  0.4, respectively. The
mean pain score at baseline for the patients in group B
was 5.9  2.3. After treatment, mean pain scores on
day 1, 2, 3, 4, 5, and 6 were 5.3  2.1, 4.5  2.0,
3.1  1.8, 1.9  1.7, 0.9  1.2, and 0.2  0.7,
respectively. These data (Table I and Figure 3) indicate
a signiﬁcant reduction in pain in group A (i.e., faster
reduction in pain) compared with group B (P < .001
using unpaired t test).Intergroup comparison of days taken for ulcer
healing and adhesive retention time
Figure 4 shows that the mean time required for ulcer
healing was signiﬁcantly less in group A (3.7  1.3
days, range 2-7 days) than that of group B (5.3  1.2
days, range 3-7 days, P < .001). The mean adhesive
retention time for drug agent in group A was similar
to that of group B (2.1  1.2 h, range 0.5-6 h vs
1.8  0.8 h, range 1.0-4 h, respectively, P ¼ .30).Adverse effects
None of the patients in our study reported any serious
adverse effects because of the study drugs. In the
doxycycline hyclate group, 8 patients experienced
Table I. Pain incidence in VAS before and after treatment
Time interval
Group A Group B
Mean VAS  SD
Difference from
baseline
% Reduction
from baseline t* P Mean VAS  SD
Difference from
baseline
% Reduction
from baseline t* P
Pretreatment 6.4  2.3 e e e 5.9  2.3 e e e
D 1 3.7  2.2 2.7  1.9 42 6.65
<.001
5.3  2.1 0.7  1.0 12 3.40
<.001
D 2 2.3  1.8 4.1  1.8 64 11.16
<.001
4.5  2.0 1.4  1.5 24 4.59
<.001
D 3 0.9  1.2 5.5  1.9 86 14.51
<.001
3.1  1.8 2.8  2.2 47 6.41
<.001
D 4 0.4  0.9 6.0  2.2 94 13.62
<.001
1.9  1.7 4.0  2.1 68 9.72
<.001
D 5 0.1  0.4 6.3  2.4 98 13.23
<.001
0.9  1.2 5.0  1.9 85 13.31
<.001
D 6 0.1  0.4 6.3  2.4 98 13.23
<.001
0.2  0.7 5.7  2.1 97 13.72
<.001
D 7 0.1  0.4 6.3  2.3 98 13.89
<.001
0.0  0.0 5.9  2.3 100 12.93
<.001
D 8 0.0  0.2 6.4  2.3 100 e 0.0  0.0 5.9  2.3 100 e
D 9 0.0  0.0 6.4  2.3 100 e 0.0  0.0 5.9  2.3 100 e
D 10 0.0  0.0 6.4  2.3 100 e 0.0  0.0 5.9  2.3 100 e
D, day; SD, standard deviation; t* e paired t test (P value assessed from t*).
Fig. 3. Pain incidence in VAS before and after treatment (* denotes signiﬁcant pain reduction).
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cation of drug.DISCUSSION
RAS is a common oral disorder affecting 5%-66% of
examined adult patient groups.14 Although many
exacerbating factors have been identiﬁed, the cause as
yet remains unknown. The difﬁculty in establishing the
exact nature of aphthous stomatitis is in part because of
the nonspeciﬁc histopathologic features of the ulcers
and the lack of any reproducibly identiﬁable cause,
endogenous or exogenous.15 Although the trigger of an
episode of RAU is unknown, extensive investigations
in large patient series have identiﬁed a range of local,
hematologic, gastrointestinal, immunologic, genetic,nutritional, allergic, psychological, and medication
reactions as probable triggers in some RAU patients.16
Various pathogenic factors have been implicated in
the causation of RAS. Interstitial collagenases (MMP-1
and MMP-8) are enzymes that are able to degrade the
main oral mucosal collagen types I and III. It has been
suggested that interstitial collagenases MMP-8 and
MMP-1 play a role in tissue destruction events in RAU.
Tetracyclines have been shown to inhibit prostaglandin
production, suppress leukocyte activities, and inhibit
collagenase and gelatinase activities as well as the
oxidative activation of their latent forms.6 As there is no
speciﬁc management for RAS,17 this study was
undertaken to examine pain reduction in RAS following
topical application of doxycycline hyclate, an inhibitor
of MMPs.
Fig. 4. Intergroup comparison of days required for ulcer healing (bottom panel) and adhesive retention time (top panel).
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the treatment of RAS. Gorsky et al. conducted a cross-
over trial to assess the efﬁcacy of 0.2% minocycline and
0.25% tetracycline oral rinses in patients with frequent
episodes of RAS. Minocycline mouthwashes as
compared with topical tetracycline rinses resulted in
signiﬁcantly improved pain control, by reducing the
severity and duration of pain.18 Denman and Schiff
conducted a study on 20 patients with recurrent oral
ulceration to determine the efﬁcacy of tetracycline
hydrochloride as a mouthwash given 5 mL 3 times a day
for 16 weeks. In this research, tetracycline was efﬁca-
cious in signiﬁcantly reducing the pain and frequency of
RAS.19 Henricsson and Axéll in a crossover trial also
found a reduction in the number of ulcers and pain
following the use of chlortetracycline for RAS.20
Apart from tetracyclines, antibiotic used for
management of RAS includes penicillin. Both Kerr
et al. in a study of 100 participants and Zhou et al. in
a study of 258 subjects with RAS found topical appli-
cation of 50 mg penicillin G potassium troches effective
and safe in the treatment of minor RAS. Troches were
consecutively applied 4 times per day for 4 days, and
this short course therapy signiﬁcantly reduced ulcer size
and alleviated ulcer pain.21,22
Few studies have explored the therapeutic effective-
ness of doxycycline hyclate in RAS. In a study con-
ducted by Ylikontiola et al., doxycycline was used ina powdered form as in our study but the adhesive used to
retain the medicament was isobutyl cyanoacrylate.6
Another study used subantimicrobial dose of doxycy-
cline 20 mg to prevent the recurrence of RAS.23 The
present study using powdered doxycycline in a denture
adhesive base is the ﬁrst study of this kind attempted for
the pain palliation in RAS patients. In the present study,
100 mg of doxycycline hyclate tablet was crushed and
appropriate amount of the powder was mixed with
denture adhesive for topical application over the ulcer by
mixing with few drops of saline solution at their ﬁrst
visit. Re-evaluation of the patients was conducted on day
10. This approach produced highly signiﬁcant reduction
in pain scores. The placebo group also rendered
a signiﬁcant pain reduction after administration of the
crushed placebo tablet over the ulcers after 7 days and
this could be explained by the fact that the adhesive
covering that was provided over the ulcers may have
rendered mechanical protection to the mucosa and hel-
ped hasten healing. Although signiﬁcant pain reduction
was present in both the groups, the rate of pain reduction
was faster in doxycycline group emphasizing the thera-
peutic efﬁcacy of this drug. Our results are similar to the
study conducted by Ylikontiola et al. suggesting that the
diverse biochemical properties of doxycycline help in
alleviating RAS pain.6
The time required for ulcer healing was 3.7  1.3
days in the doxycycline hyclate group, whereas it was
OOOO ORIGINAL ARTICLE
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comparative study conducted by Gorsky et al. for
assessing the efﬁcacy of topical minocycline and
tetracycline rinses in RAS also showed that the duration
of ulcers was signiﬁcantly reduced in patients using
topical minocycline as therapy.18
Denture adhesive was used as a vehicle for retention
of the medicament in the present study. This was in
accordance with the study conducted by Muzio et al. in
which topical clobetasol propionate in an adhesive
denture paste was administered to the patients with
RAS and a good retention of the medicament to the
mucosa was achieved.24 The mean adhesive retention
time was approximately 2 h in both groups.
The management of RAS using doxycycline hyclate
appears to be an efﬁcacious cost-effective therapy
because a single application rendered about 65%
pain reduction by day 2 posttreatment, whereas
other studies with other drugs require up to 10 days
to demonstrate a clinically signiﬁcant response.24
Although pain reduction after 7 days of treatment was
signiﬁcant in both the groups, the intergroup compar-
ison revealed a highly signiﬁcant reduction in pain and
days taken for ulcer healing in the doxycycline hyclate
group as compared with the placebo group, thus
substantiating the efﬁcacy of the study drug. The ﬁrst
day posttreatment percentage of pain reduction in VAS
achieved with the doxycycline hyclate group was 42%
whereas with the placebo group, it was 12% with
a P value <.001.Limitations
Although the results of the study are encouraging, there
were a few limitations worth considering. The study
was a single-blinded, placebo-controlled study, and
double blinding offers greater validity. The application
of the medicament to the posterior regions of the oral
cavity was relatively difﬁcult because of access.
Patients with multiple and large ulcers may not be
treated efﬁcaciously with doxycycline hyclate. Pain
data were derived from subjective assessment, so there
could be interindividual variations in the perception of
pain. As the pain scale sheet was given to the patient for
marking the posttreatment percentage of pain each day
until the ulcer healed, subjects who were illiterate faced
problem and had to seek help from other literate indi-
viduals in the family.
In the present study, the medicament was applied to
the ulcers by the dental professional. It is recommended
that if commercial preparation of topical doxycycline
hyclate in a proper adhesive is made available in the near
future, the patient could self-apply the medicament.
Moreover, the frequency of application could also be
made based on the patients’ convenience.In conclusion, crushed doxycycline tablets in denture
adhesive produced favorable results and appears
advantageous because of its cost effectiveness, single
application, and faster symptomatic relief than other
drugs. We believe that single application of the anti-
biotic doxycycline is a novel attempt to improve the
compliance of patients with RAS. Further studies are
recommended on a larger sample of patients, over
a longer follow-up period, possibly using a double-
blind design along with the evaluation of immunologic
markers, to minimize the effects of confounding factors
and to maximize the sensitivity for detecting subtle
changes of the mucosa during the course of the
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